Pierre Fabre Laboratories和Scorpion Therapeutics宣布开始PFL-241/STX-241的I/II期临床试验-动脉橙

Pierre Fabre Laboratories和Scorpion Therapeutics宣布开始PFL-241/STX-241的I/II期临床试验

2024-10-08 businesswire 等2家媒体报道商业合作





Pierre Fabre Laboratories和Scorpion Therapeutics宣布开始PFL-241/STX-241的I/II期临床试验，PFL-241/STX-241是一种靶向EGFR外显子19或21突变并伴有C797S突变的高选择性酪氨酸激酶抑制剂。该试验旨在评估该药物作为单一疗法对携带这些突变的局部晚期或转移性非小细胞肺癌患者的安全性，耐受性，药代动力学，药效学和初步疗效。NSCLC是最常见的肺癌形式，EGFR突变是常见的疾病驱动因素。这些公司认为PFL-241/STX-241有可能成为这些患者的最佳治疗选择。（摘要由动脉网AI生成）

关联公司

 Pierre Fabre LaboratoriesScorpion Therapeutics

2024-10-08 Pierre Fabre Laboratories and Scorpion Therapeutics Announce First Patient Dosed in Phase I/II Clinical Trial of PFL-241/STX-241, a Mutant-Selective Inhibitor Intended to Treat Locally Advanced or Metastatic Non-Small Cell Lung Cancer

businesswire
2024-10-09 Pierre Fabre & Scorpion Therapeutics announce new Phase I/II clinical trial for an innovative treatment in oncology.

PHARMA FOCUS ASIA